Anders Kronborg, M.Sc. Economics

CHIEF EXECUTIVE OFFICER

Mr Kronborg is a seasoned executive with more than 25 years experience as CEO, CFO or COO. After he graduated as economist from Copenhagen University he spent 7 years in different roles in the ministry of Finance. From 2007-2015 Mr Kronborg worked for Kinnevik – a Swedish investment company listed in Stockholm – from 2012-2015 as COO for the whole group,  getting private companies ready to go public and listing them together with other investors.

More recently (2015-2022) Mr Kronborg was CFO and interim CEO in LEO Pharma – a global Pharma company specialized in skin diseases.

Hanne Leth Hillman, M.Sc.

CHIEF FINANCIAL OFFICER

Hanne Leth Hillman is a finance executive with broad experience across Finance, Equity Market transactions, Investor Relations and Corporate Communications.

Hanne’s career has been focused on the Life Science sector and she has held senior positions in both public and private biotech and medical device companies. Before this, she worked for more than 10 years in investment banking and equity research.

Hanne holds a MSc in Business Administration and International Finance from the Aarhus School of Business and Social Sciences and has a certificate of Board Leadership from Copenhagen Business School Executive.

Thomas Jørgensen, MSc

VP CMC & CLINICAL OPERATIONS

Thomas Jørgensen has more than 30 years of experience working within the global pharmaceutical industry with clinical and pre-clinical program management, alliance management and CMC development for a variety of therapeutic modalities such as peptides, biologics, live biotherapeutics, and fermentation products.

Thomas’ former appointments include Senior Director, Savara, Director, Chr Hansen Microbiome Center, Program manager, Ferring Pharmaceutical, Alliance and Program manager, Symphogen, Group leader, CMC, Astra Zeneca and Research Scientist, Novo Nordisk. 

Samra Sanni, PhD

VP DRUG RESEARCH

Samra Sanni is a biotech executive with a successful track record of discovery and development of novel peptide therapeutics within the cardio-metabolic space. Dr Sanni has significant experience from both smaller biotech and large pharma and has an impressive track record of bringing new molecules forward into clinical development. Previously, Dr Sanni served as Director of Pharmacology at Bainan Biotech and was previously employed at Antag Therapeutics and Novo Nordisk where she contributed to discovering and advancing new drugs in the company’s pipelines. Samra holds a Ph.D. in molecular pharmacology from the University of Copenhagen.

Anders Kronborg, M.Sc. Economics

CHIEF EXECUTIVE OFFICER

Mr Kronborg is a seasoned executive with more than 25 years experience as CEO, CFO or COO. After he graduated as economist from Copenhagen University he spent 7 years in different roles in the ministry of Finance. From 2007-2015 Mr Kronborg worked for Kinnevik – a Swedish investment company listed in Stockholm – from 2012-2015 as COO for the whole group,  getting private companies ready to go public and listing them together with other investors.

More recently (2015-2022) Mr Kronborg was CFO and interim CEO in LEO Pharma – a global Pharma company specialized in skin diseases.

Dr Veng has operational leadership experience from both small and large organizations and has always worked at the intersection of business and innovation.

Most recently, Dr. Veng served as CEO and co-founder of Clinical Microbiomics. During her career, she has held various senior research leadership roles, including Head of Pharmacology and DMPK at LEO Pharma, preclinical team leader at Merck & Co, and H. Lundbeck. Dr. Veng has overseen the drug discovery, nomination and clinical transition of a number of drug candidates for inflammatory and neurological disorders.

Hanne Leth Hillman, M.Sc.

CHIEF FINANCIAL OFFICER

Hanne Leth Hillman is a finance executive with broad experience across Finance, Equity Market transactions, Investor Relations and Corporate Communications.

Hanne’s career has been focused on the Life Science sector and she has held senior positions in both public and private biotech and medical device companies. Before this, she worked for more than 10 years in investment banking and equity research.

Hanne holds a MSc in Business Administration and International Finance from the Aarhus School of Business and Social Sciences and has a certificate of Board Leadership from Copenhagen Business School Executive.

Dr Veng has operational leadership experience from both small and large organizations and has always worked at the intersection of business and innovation.

Most recently, Dr. Veng served as CEO and co-founder of Clinical Microbiomics. During her career, she has held various senior research leadership roles, including Head of Pharmacology and DMPK at LEO Pharma, preclinical team leader at Merck & Co, and H. Lundbeck. Dr. Veng has overseen the drug discovery, nomination and clinical transition of a number of drug candidates for inflammatory and neurological disorders.

Thomas Jørgensen

VP CMC  & CLINICAL OPERATIONS

Thomas Jørgensen has more than 30 years of experience working within the global pharmaceutical industry with…

clinical and pre-clinical program management, alliance management and CMC development for a variety of therapeutic modalities such as peptides, biologics, live biotherapeutics, and fermentation products.

Thomas’ former appointments include Senior Director, Savara, Director, Chr Hansen Microbiome Center, Program manager, Ferring Pharmaceutical, Alliance and Program manager, Symphogen, Group leader, CMC, Astra Zeneca and Research Scientist, Novo Nordisk. 

Samra Sanni, PhD

VICE PRESIDENT OF DRUG RESEARCH

Samra Sanni is a biotech executive with a successful track record of discovery and development of novel peptide therapeutics within the cardio-metabolic space.

Dr Sanni has significant experience from both smaller biotech and large pharma and has an impressive track record of bringing new molecules forward into clinical development. Previously, Dr Sanni served as Director of Pharmacology at Bainan Biotech and was previously employed at Antag Therapeutics and Novo Nordisk where she contributed to discovering and advancing new drugs in the company’s pipelines. Samra holds a Ph.D. in molecular pharmacology from the University of Copenhagen.